Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled trial of GH001 in treatment-resistant depression
2022-000574-26Phase 2Active
- Sponsor
- GH Research PLC
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mebufotenin in treatment-resistant depression (TRD) and major depressive disorder (MDD) (3 arms), sponsored by GH Research PLC. Primary endpoint: Safety and efficacy. Started Sep 2022; status: active.
02
Drugs
mebufotenin
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2022-000574-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000574-26.